Analysis of glycosylation in lupus anti-DNA antibodies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to analyze the glycosylation patterns of anti-DNA antibodies in patients with systemic lupus erythematosus (SLE). A total of 140 adult patients will be recruited from the University Hospital of Montpellier and Nîmes, and followed for one year. Blood samples will be collected at the start, after one year, and during any disease flare, with serum stored for analysis. The glycosylation status of the antibodies will be determined using mass spectrometry and correlated with disease activity measured by the SLEDAI score.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients presenting with LED according to the ACR/EULAR 2019 criteria, all clinical forms combined, quiescent or in flare with positive native anti-DNA antibodies, providing oral informed consent.

Exclusion Criteria:

* Patients under protection of justice or unable to receive a clear information.
* High probability of non-compliance with the protocol or withdrawal during the study
* Already involved in another interventional clinical study

Where it's running

• Montpellier University Hospital
  Montpellier, France Recruiting
• Nimes University Hospital
  Nîmes, France Recruiting

Study contacts

• Study coordinator: Thierry VINCENT, MD
• Email: t-vincent@chu-montpellier.fr
• Phone: +334 67 33 71 35

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• AI-powered personalized heat risk alerts for adults with chronic conditions

  A smartphone app-based test will see if AI-driven, personalized heat risk alerts reduce heat-related illness symptoms in adults with chronic diseases.

  Recruiting National University of Medical Sciences, Pakistan · Gujranwala, Punjab Province · NCT07825831

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• Music-4-MS: A 12-week music-based program to support thinking skills in people with MS

  A 12-week music-based program is tested to see if it helps cognitive function and mood in people living with multiple sclerosis.

  Recruiting University of Texas at Austin · Austin, Texas · NCT07759115

• ATG-201 in adults with autoimmune diseases

  This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.

  Recruiting Phase 1 Antengene Corporation · Bengbu, Anhui and 21 other locations · NCT07732309

• Mobile reminder app to help people with chronic disease and memory loss stick to their meds

  This study tests whether a smartphone reminder app can improve how well adults with chronic diseases and memory impairment take their prescribed medications.

  Recruiting at 2 sites Mansoura University · Gamasa, Dakahlia Governorate and 1 other locations · NCT07718334

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.